DoubleBlind Claims Its Ad Was the ‘First-Ever’ U.S. Psychedelic Destigmatization Campaign — It Wasn’t
DoubleBlind claims its recently-unveiled New York City billboard is a lot of things, except what it actually is: a giant advertisement.
Indie Film ‘Debbie and Doug Drop Acid in the Desert’ is a Visual and Emotional Trip
'Debbie and Doug Drop Acid in the Desert' director, Scott Brown, talks mind-altering drugs, creating psychedelic visual effects, and dealing with depression.
Ayahuasca Healings’ Trinity de Guzman calls coronavirus “a necessary purge”
“The Corona Virus is a necessary purge of what is no longer in resonance,” Trinity de Guzman wrote in a recent email to his followers.
Psymposia 2020 Staff Book Picks
The Psymposia staff reflects on some of the books that kept us company throughout 2020, which we'd like to recommend to our readers for 2021. The list includes works of intersectional analysis, psychedelic history, surveillance capitalism, and more. We hope you appreciate these insights as much as we do.
COMPASS Pathways Is Trying to Patent Psilocybin for More Mental Health Conditions Than You Can Name
News that COMPASS Pathways is attempting to patent psychedelic therapy room specifications and therapist behaviors started an online firestorm about the company’s “monopolistic and shady behaviors,” but so far the debates have missed the biggest threats lurking in COMPASS’s international patent applications.
Timothy Leary’s Castalia Foundation Has Been Co-opted to Promote Conspiracy Theories about COVID and Elite Pedophile Rings
The Castalia Foundation — originally founded in part by Timothy Leary — "resurfaced" in 2020 with anti-mask content, praise for Donald Trump, and paranoid discussion around the sexual abuse of children.
Every Disclosed Conflict of Interest at Psychedelic Science 2023
All the financial conflict disclosures from Psychedelics Science 2023 speakers, in one handy list.
Correcting the Record: Addressing The New York Times’ Deceptive Coverage of Psymposia
Rather than unpacking the actual causes of Lykos Therapeutics' disastrous Phase 3 trials and FDA rejection, The New York Times produced a work of fictitious propaganda that prioritizes corporate interests over public health.
A persuasive case for the decriminalization of drugs, Pt. 1
If neither the state nor defenders of our continued drug policies can provide a rational justification for the continued practice of incarcerating drug users, then the use of punishment by the state against drug users is morally unjustified.
#29 – The Tesla of Mental Health?
Brian Normand and David Nickles are joined by Psymposia Senior Writer Russell Hausfeld to discuss MindMed's CEO, Jamon Rahn's, recent claims that his company "may be creating effectively the Tesla of mental health,” and that the company is now a "$1B+ Unicorn.”